In depression that is resistant to tricyclic antidepressant (TCA) therapy, the substitution of a selective serotonin re-uptake inhibitor (SSRI), clomipramine, or a monoamine oxidase (MAO) inhibitor has been recommended. However, adding an additional antidepressant medication from a different drug cl
Quetiapine augmentation in treatment-resistant depression: a naturalistic study
✍ Scribed by Marina Šagud; Alma Mihaljević-Peleš; Dorotea Mück-Šeler; Miro Jakovljević; Nela Pivac
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 122 KB
- Volume
- 187
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Objective Olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment‐resistant depression (TRD). However, studies of olanzapine augmentation of other antidepressants are few. We investigated the efficacy and safety of olanz
Drug resistant depression is a confounding entity. More so in populations of elderly depressives where addition of lithium or antidepressant combinations are possibly hazardous. We present an open-trial of thyroxine in elderly patients diagnosed as suffering from resistant depression. Methods -Thyro